Scarica l'app Stockscreener
85.86
1.94%
1.69
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché EW Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$84.17
Aprire:
$84.39
Volume 24 ore:
2.88M
Relative Volume:
0.74
Capitalizzazione di mercato:
$49.83B
Reddito:
$5.88B
Utile/perdita netta:
$1.34B
Rapporto P/E:
36.55
EPS:
2.3489
Flusso di cassa netto:
$799.60M
1 W Prestazione:
-0.46%
1M Prestazione:
-0.45%
6M Prestazione:
+11.74%
1 anno Prestazione:
+16.68%
Intervallo 1D:
$84.33
$86.56
Intervallo di 1 settimana:
$83.66
$86.64
Portata 52W:
$65.94
$87.89
Edwards Lifesciences Corp Stock (EW) Company Profile
Nome
Edwards Lifesciences Corp
Settore
Industria
Telefono
(949) 250-2500
Indirizzo
ONE EDWARDS WAY, IRVINE, CA
Confronta EW con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
EW
Edwards Lifesciences Corp
|
85.88 | 48.84B | 5.88B | 1.34B | 799.60M | 2.3489 |
|
ABT
Abbott Laboratories
|
127.99 | 219.88B | 43.84B | 13.90B | 6.92B | 7.9725 |
|
BSX
Boston Scientific Corp
|
97.64 | 141.54B | 19.35B | 2.78B | 3.82B | 1.8696 |
|
SYK
Stryker Corp
|
366.27 | 133.39B | 24.38B | 2.94B | 4.07B | 7.6159 |
|
MDT
Medtronic Plc
|
100.25 | 124.82B | 34.76B | 4.79B | 5.21B | 3.7017 |
Edwards Lifesciences Corp Stock (EW) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-12-18 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2025-11-03 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2025-10-29 | Aggiornamento | Jefferies | Hold → Buy |
| 2025-10-29 | Aggiornamento | Wolfe Research | Underperform → Peer Perform |
| 2025-10-08 | Downgrade | Oppenheimer | Outperform → Perform |
| 2025-10-07 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2025-07-29 | Aggiornamento | BTIG Research | Neutral → Buy |
| 2025-04-24 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2025-01-30 | Aggiornamento | Stifel | Hold → Buy |
| 2025-01-16 | Downgrade | Wolfe Research | Peer Perform → Underperform |
| 2024-12-16 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2024-10-11 | Ripresa | Morgan Stanley | Equal-Weight |
| 2024-09-18 | Downgrade | Jefferies | Buy → Hold |
| 2024-07-31 | Aggiornamento | Daiwa Securities | Neutral → Outperform |
| 2024-07-29 | Aggiornamento | Wolfe Research | Underperform → Peer Perform |
| 2024-07-25 | Downgrade | BofA Securities | Buy → Neutral |
| 2024-07-25 | Downgrade | JP Morgan | Overweight → Neutral |
| 2024-07-25 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2024-07-25 | Downgrade | TD Cowen | Buy → Hold |
| 2024-07-25 | Downgrade | Truist | Buy → Hold |
| 2024-05-30 | Iniziato | Goldman | Buy |
| 2024-05-22 | Aggiornamento | Citigroup | Neutral → Buy |
| 2024-05-14 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2024-03-07 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2024-02-02 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2024-01-04 | Downgrade | Evercore ISI | Outperform → In-line |
| 2023-12-11 | Downgrade | Citigroup | Buy → Neutral |
| 2023-11-28 | Downgrade | Wolfe Research | Peer Perform → Underperform |
| 2023-09-26 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2023-07-19 | Iniziato | Robert W. Baird | Outperform |
| 2023-05-30 | Ripresa | Morgan Stanley | Overweight |
| 2023-03-29 | Iniziato | UBS | Neutral |
| 2023-03-08 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2023-02-06 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2023-01-31 | Downgrade | Bernstein | Outperform → Underperform |
| 2023-01-30 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2022-12-06 | Downgrade | Stifel | Buy → Hold |
| 2022-10-28 | Downgrade | Oppenheimer | Outperform → Perform |
| 2022-10-26 | Iniziato | Mizuho | Buy |
| 2022-10-18 | Iniziato | Barclays | Overweight |
| 2022-10-12 | Iniziato | Jefferies | Buy |
| 2022-07-29 | Downgrade | Canaccord Genuity | Buy → Hold |
| 2022-04-13 | Iniziato | Truist | Buy |
| 2022-04-06 | Iniziato | Wolfe Research | Outperform |
| 2022-03-16 | Aggiornamento | Bernstein | Mkt Perform → Outperform |
| 2022-03-02 | Ripresa | BofA Securities | Neutral |
| 2022-02-02 | Aggiornamento | UBS | Neutral → Buy |
| 2022-01-27 | Reiterato | Citigroup | Buy |
| 2022-01-27 | Reiterato | Evercore ISI | Outperform |
| 2022-01-27 | Reiterato | Raymond James | Outperform |
| 2022-01-27 | Reiterato | Stifel | Buy |
| 2022-01-27 | Reiterato | UBS | Neutral |
| 2021-12-17 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2021-12-15 | Aggiornamento | Citigroup | Neutral → Buy |
| 2021-12-10 | Iniziato | RBC Capital Mkts | Outperform |
| 2021-12-06 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2021-07-30 | Reiterato | Canaccord Genuity | Buy |
| 2021-07-30 | Reiterato | Deutsche Bank | Hold |
| 2021-07-30 | Reiterato | Jefferies | Buy |
| 2021-07-30 | Reiterato | Morgan Stanley | Overweight |
| 2021-07-30 | Reiterato | Oppenheimer | Outperform |
| 2021-07-30 | Reiterato | Stifel | Buy |
| 2021-07-30 | Reiterato | UBS | Neutral |
| 2021-07-30 | Reiterato | Wells Fargo | Equal Weight |
| 2021-05-25 | Iniziato | Barclays | Overweight |
| 2021-04-15 | Iniziato | Atlantic Equities | Neutral |
| 2021-04-05 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2020-12-16 | Downgrade | Citigroup | Buy → Neutral |
| 2020-12-11 | Reiterato | Canaccord Genuity | Buy |
| 2020-09-11 | Iniziato | Wolfe Research | Underperform |
| 2020-04-28 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2020-04-17 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2020-03-05 | Iniziato | Citigroup | Buy |
| 2020-02-13 | Iniziato | Goldman | Neutral |
| 2020-02-06 | Ripresa | BTIG Research | Neutral |
| 2020-01-10 | Iniziato | Oppenheimer | Outperform |
| 2020-01-02 | Downgrade | Evercore ISI | Outperform → In-line |
| 2019-10-24 | Reiterato | Canaccord Genuity | Buy |
| 2019-09-23 | Iniziato | Piper Jaffray | Overweight |
| 2019-07-24 | Reiterato | BofA/Merrill | Buy |
| 2019-03-18 | Reiterato | Canaccord Genuity | Buy |
| 2019-01-18 | Aggiornamento | BofA/Merrill | Neutral → Buy |
| 2019-01-03 | Iniziato | Deutsche Bank | Hold |
| 2018-11-28 | Iniziato | UBS | Neutral |
| 2018-10-16 | Iniziato | Barclays | Underweight |
| 2018-10-02 | Downgrade | BofA/Merrill | Buy → Neutral |
| 2018-10-02 | Downgrade | Guggenheim | Buy → Neutral |
Mostra tutto
Edwards Lifesciences Corp Borsa (EW) Ultime notizie
Edwards Lifesciences completes key study on SAPIEN XT THV - MSN
Edwards Lifesciences (NYSE:EW) Will Want To Turn Around Its Return Trends - simplywall.st
Econ Financial Services Corp Acquires 15,836 Shares of Edwards Lifesciences Corporation $EW - MarketBeat
Ninety One UK Ltd Buys 969,030 Shares of Edwards Lifesciences Corporation $EW - MarketBeat
Ninety One North America Inc. Acquires 71,017 Shares of Edwards Lifesciences Corporation $EW - MarketBeat
Edwards Lifesciences Corporation (NYSE:EW) Short Interest Down 19.2% in December - MarketBeat
VIRGINIA RETIREMENT SYSTEMS ET Al Purchases 56,000 Shares of Edwards Lifesciences Corporation $EW - MarketBeat
Cwm LLC Purchases 43,065 Shares of Edwards Lifesciences Corporation $EW - MarketBeat
Edwards Lifesciences (NYSE:EW) Shares Unloaded Rep. Josh Gottheimer - MarketBeat
Mirova US LLC Has $219.47 Million Position in Edwards Lifesciences Corporation $EW - MarketBeat
Farmers & Merchants Investments Inc. Sells 15,037 Shares of Edwards Lifesciences Corporation $EW - MarketBeat
Stifel Upgrades Edwards Lifesciences (EW) - MSN
Edwards Lifesciences Corp Stock Price Live, Charts & News - The Economic Times
Edwards Sapien M3 Valve Gets FDA Approval - Orange County Business Journal
World Investment Advisors Has $2.81 Million Stake in Edwards Lifesciences Corporation $EW - MarketBeat
Edwards Lifesciences Corporation $EW Shares Sold by Litman Gregory Wealth Management LLC - MarketBeat
Edwards Lifesciences Corp (EW) Stock Price History & Data - Traders Union
Covea Finance Takes Position in Edwards Lifesciences Corporation $EW - MarketBeat
Edwards Lifesciences Corporation (NYSE:EW) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
How Do Investors Really Feel About Edwards Lifesciences Corp? - Sahm
Transcatheter Mitral Valve Replacement System Receives FDA Clearance - Diagnostic and Interventional Cardiology
HALPER SADEH LLC ENCOURAGES EDWARDS LIFESCIENCES CORPORATION SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS - Finviz
Edwards Lifesciences Corp (EW) Stock Price, Trades & News - GuruFocus
Edwards Lifesciences Corporation $EW Shares Sold by OLD National Bancorp IN - MarketBeat
FDA Approves Edwards Lifesciences' SAPIEN M3 Mitral Valve Replacement System as First Transseptal Transcatheter Therapy - BioSpace
Edwards Lifesciences (EW): Assessing Valuation After Recent Share Price Strength - Yahoo Finance
EW SEC FilingsEdwards Lifesciences Corp 10-K, 10-Q, 8-K Forms - Stock Titan
Edwards lands first FDA approval for transcatheter MVR - BioWorld MedTech
The Zacks Analyst Blog Highlights Cardinal Health, Medtronic, Intuitive Surgical and Edwards Lifesciences - Yahoo Finance
Edwards Lifesciences Says FDA Approves Valve Replacement System - marketscreener.com
Edwards wins FDA approval for Sapien M3 mitral valve, marking first transseptal transcatheter therapy - MassDevice
Edwards Lifesciences’ SAPIEN M3 becomes first FDA-approved mitral valve system - Investing.com
Edwards Lifesciences gets FDA approval for SAPIEN M3 mitral valve system By Investing.com - Investing.com South Africa
Edwards Lifesciences gets FDA approval for SAPIEN M3 mitral valve system - Investing.com Canada
FDA approves Edwards Lifesciences' Sapien M3 mitral valve replacement system as first transseptal transcatheter therapy - marketscreener.com
FDA Approves Edwards Lifesciences' SAPIEN M3 Mitral Valve Replacement System as First Transseptal Transcatheter Therapy – Company AnnouncementFT.com - Financial Times
OFI Invest Asset Management Raises Stock Holdings in Edwards Lifesciences Corporation $EW - MarketBeat
Edwards Lifesciences Corporation $EW Shares Sold by Legacy Wealth Asset Management LLC - MarketBeat
Edwards Lifesciences Corp. stock outperforms competitors on strong trading day - MarketWatch
Edwards Lifesciences Advances Smart Surgery Monitoring With Completed SMART TRENDS Study - TipRanks
Seilern Investment Management Ltd Sells 183,101 Shares of Edwards Lifesciences Corporation $EW - MarketBeat
How JP Morgan’s Upgrade and 2026 Conference Spotlight Will Impact Edwards Lifesciences (EW) Investors - simplywall.st
Edwards Lifesciences (BSP:E1WL34) EV-to-OCF : 46.58 (As of Dec. 20, 2025) - GuruFocus
Edwards Lifesciences Corporation $EW Shares Sold by Texas Permanent School Fund Corp - MarketBeat
Profit Review: How Edwards Lifesciences Corporation stock compares to industry benchmarksPrice Action & Capital Efficiency Focused Ideas - Улправда
Edwards Lifesciences Corporation (EW) Stock Price | Live Quotes & Charts | NYSE - StocksToTrade
How Edwards Lifesciences Corporation stock performs in rate cut cyclesJuly 2025 Setups & Daily Profit Focused Stock Screening - Улправда
What makes Edwards Lifesciences Corporation stock attractive to growth fundsJuly 2025 Opening Moves & Community Verified Trade Alerts - ulpravda.ru
Edwards Lifesciences (WBO:EWLS) EV-to-OCF : 44.69 (As of Dec. 19, 2025) - GuruFocus
Edwards Lifesciences (NYSE:EW) Updates FY 2025 Earnings Guidance - MarketBeat
Amiral Gestion Has $21.99 Million Position in Edwards Lifesciences Corporation $EW - MarketBeat
Edwards Lifesciences Corp Azioni (EW) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.15%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):